Carcinoma, non-small-cell lung Trials in Caen, France
Conditions / Carcinoma, non-small-cell lung / Caen, France
Carcinoma, non-small-cell lung is a medical condition with active clinical research programs worldwide.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | COMPLETED | PHASE2 |
| NCT00300885 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE3 |
| NCT00054795 | Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) | COMPLETED | PHASE3 |
| NCT00932893 | An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | COMPLETED | PHASE3 |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | COMPLETED | PHASE3 |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING | — |
| NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer | COMPLETED | PHASE3 |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | TERMINATED | PHASE3 |
| NCT00932451 | An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | COMPLETED | PHASE2 |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | RECRUITING | — |